FDA Approves Keytruda®

On November 13, 2020, the FDA approved pembrolizumab (Keytruda®)  in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA approved test.

FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer 

• Category: FDA Approval, Special Topics
• Tag: FDA Approval, Immunotherapy, TNBC